{"name":"Walvax Biotechnology Co., Ltd.","slug":"walvax-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Pfizer PCV13","genericName":"Pfizer PCV13","slug":"pfizer-pcv13","indication":"Prevention of invasive pneumococcal disease in infants and children","status":"phase_3"},{"name":"Walvax PCV13-TT","genericName":"Walvax PCV13-TT","slug":"walvax-pcv13-tt","indication":"Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae","status":"phase_3"},{"name":"vaccination PNEUMOVAX 23","genericName":"vaccination PNEUMOVAX 23","slug":"vaccination-pneumovax-23","indication":"Prevention of invasive pneumococcal disease in adults and children ≥2 years of age","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Sanofi Pasteur Menactra® vaccine","genericName":"Sanofi Pasteur Menactra® vaccine","slug":"sanofi-pasteur-menactra-vaccine","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in individuals 9 months of age and older","status":"marketed"},{"name":"Yuxi Walvax MPV ACYW® vaccine","genericName":"Yuxi Walvax MPV ACYW® vaccine","slug":"yuxi-walvax-mpv-acyw-vaccine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Pfizer PCV13","genericName":"Pfizer PCV13","slug":"pfizer-pcv13","phase":"phase_3","mechanism":"PCV13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae.","indications":["Prevention of invasive pneumococcal disease in infants and children","Prevention of pneumococcal pneumonia and otitis media in pediatric populations"],"catalyst":""},{"name":"Sanofi Pasteur Menactra® vaccine","genericName":"Sanofi Pasteur Menactra® vaccine","slug":"sanofi-pasteur-menactra-vaccine","phase":"marketed","mechanism":"Menactra is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by presenting polysaccharide antigens linked to a carrier protein.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in individuals 9 months of age and older"],"catalyst":""},{"name":"Walvax PCV13-TT","genericName":"Walvax PCV13-TT","slug":"walvax-pcv13-tt","phase":"phase_3","mechanism":"Walvax PCV13-TT is a conjugate vaccine that stimulates the body's immune response to protect against pneumococcal disease.","indications":["Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae"],"catalyst":""},{"name":"Yuxi Walvax MPV ACYW® vaccine","genericName":"Yuxi Walvax MPV ACYW® vaccine","slug":"yuxi-walvax-mpv-acyw-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"vaccination PNEUMOVAX 23","genericName":"vaccination PNEUMOVAX 23","slug":"vaccination-pneumovax-23","phase":"phase_3","mechanism":"PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","indications":["Prevention of invasive pneumococcal disease in adults and children ≥2 years of age","Prevention of pneumococcal pneumonia, bacteremia, and meningitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTm9CS3NIbEN3OXctYkY3cVB0UkRET185UDhiV1IwcUpYRkhFQWZEVG5oMlZvajlTLW8xNHlCYlpsZEtSRklGd25QUmFVQ2o5SDJiOTE3alRYcjBXLS15Q2RvQnFpS2hRVkdSLXd6ckdNMUJfQ2FiekE4TXJ6TVpXaGhNMWdEajhOX0lqak9LSXBXMWR4V1ZtZzlR?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Pneumococcal Vaccines Market Future Business Opportunities - openPR.com","headline":"Pneumococcal Vaccines Market Future Business Opportunities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQUDdXSnlMTXpEUnNzYWZpLXNBaFBuNDB3c3ZoRzJkd0tWbDMtYzJYbHdSNnY4N1Z0ZnVUb0phWmE3eW55a0ViU3E5Ri02OXpaUV9IeEg2SHZVNWVsUC1IQVdvSlhNaXRDWjJZRmRuMFJ6LUE4RUJoQW1SM2t3NWRCdGNmZkhuVGpUVUxKOFJidlNRd19MSDhjNzRFNll2SlFSX2ZmNjI3VktLd3NROW9jQ1JWOXY?oc=5","date":"2025-12-01","type":"pipeline","source":"Bloomberg.com","summary":"China’s 78-Cent Flu Shots Show Price Squeeze for Vaccine Makers - Bloomberg.com","headline":"China’s 78-Cent Flu Shots Show Price Squeeze for Vaccine Makers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9QUTd6c0R3SUtGOFEyNkIyX093Z2lXeE01SHc5c2Y5Y09NeXliS1lnUTF1cHcySE50SmhRSHI1S0NlRVlORUduaG9XODNvM2ppQWFpQk5sOU5KNnBtM2hIbTFGZ0Y?oc=5","date":"2025-01-13","type":"pipeline","source":"Market.us","summary":"Pneumococcal Vaccines Market Size, Share | CAGR of 6.3% - Market.us","headline":"Pneumococcal Vaccines Market Size, Share | CAGR of 6.3%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPMlBCOFhSQUFLVm5hYzBiSFpJcGdVMVAtVl9mbWZPVVF2Z0k2UFBoYURrSzk0VW9SdXYzMHBCRjFyel82c3BwZzZjYnpFRG5UMmFLeGdiQWtXS2tlc0NzY24yQkU1OTNSWE0teW5iM2ljanlQSVdsMnBQUGdvZlhlNWNrcVRHWkJLX1QzYXRtUVp4Z2VnX3Z5R3k3Z0FRN3lxTkcxdkUwQ0dFRFNhMjREWE9EYXJ1dnBzNXZtRnhONlRKS3M2?oc=5","date":"2024-04-19","type":"pipeline","source":"Reuters","summary":"Focus: China's drugmakers can't sell mRNA shots but haven't quit yet - Reuters","headline":"Focus: China's drugmakers can't sell mRNA shots but haven't quit yet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMnkxY045R0puRUc5MUhkektPLVpjTHRRcTZ0cy1EUFRDZ1VtOUVUMzhqdUFiTXl4V1AtcVVzNk5fQVFKZzRycnh1TjNvbW5tQ2ZLenIxalE0RE5DRy1kX1dEQm41a21XTWhOcVptcV85VlZPSDU1MEx1dldYM3RwNUFsUGRka2VTZXhvMGFVT1FCZmpoSnJYenlMeE5NdVo1M2hJaTlET0puNXA3Z1luUFFyVGw?oc=5","date":"2023-08-16","type":"pipeline","source":"The Standard (HK)","summary":"China Health Care Braces for Sweeping Anti-Corruption Campaign - The Standard (HK)","headline":"China Health Care Braces for Sweeping Anti-Corruption Campaign - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE10RV91V01YU0ZTUHJfTzN3emlRdDZYWHFIT2c5b1A0bExHT1NfajNwV0l2aEhLSVE0SEZVa3dXTDRhNWxBV21HOE5UUlJNMXhpbVBmWG5yV1BvYnJiOUhzRHFjcU9GdS1sdUtPN0xidG90VzVzalU1eQ?oc=5","date":"2022-11-17","type":"pipeline","source":"Fortune Business Insights","summary":"Cancer Vaccines Market Size & Share | Global Report [2034] - Fortune Business Insights","headline":"Cancer Vaccines Market Size & Share | Global Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNZVJ4eFhSWnBncXZ4U0h6aWk1UlA2anBRNmV1OGJ6QjNBTHJGMlRFVGZqMm56UDg2X2xVY1VOaXBUcWhZWGcxalJVZVpSV3F5bXhPTWY1ZWRlM1c5RERrVGtBcmdVZDRsOENmZk1LOWt6REFUbjFQTHVycDhfX1JaQTR6cW1lWXZFZjc2RDd0QVJTM09OQ0ZJc05lUkFPVkF3VVFWazM1b1JQbmFKV1YyNmZiOVEwbS1LOW96bEJZMWZUZm1ITTdxdkNzMk56VXByWDBrWEpzNW1EalE?oc=5","date":"2022-09-30","type":"regulatory","source":"Reuters","summary":"A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia - Reuters","headline":"A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQRWk0bHN6MlFZWDBBd2dNVmJMbHVvbEhWX1QwcHJheUdvdFVIamhJRmZ2TTNpT1BmN3RvelBzNWMySXlrUnBwUGFYa2FkWlozYVluUVNSQk1WZWpROFVzUUo3OGFhUjBfalFxamVFTVFRZzVkdHJoMVZXOXlSdXdQU2FUOU56VUlnWEVMSHliSjFCRWNrdDJqYXdDRU9uc29tVGxoYnZOa0lGYVQtLTNacXR6NVFnekdkbGoxelBBbGFUdFdhZkYtUA?oc=5","date":"2021-11-03","type":"pipeline","source":"Bloomberg.com","summary":"China Is Leveraging Its Vaccine Diplomacy Beyond Covid Shots - Bloomberg.com","headline":"China Is Leveraging Its Vaccine Diplomacy Beyond Covid Shots","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQTDI5a1FuTEFiaVZEcm1YMEdSWUY2MG9aX0VJN1d0Rmg0TEs2NDdSOEd1ZWFOZWdCNkVZVlVYMkwtejFRSWhRR1dnalN5QTlVR0U2RzMyWTdrRWYtTm5VZ3NHZE16WkVEbjY2d2JDUHY3X0ZobjNXbDV3N0lZUGM1MENmUlA5MmthV3NsdmhXVGMycVFVYmQ3cTln?oc=5","date":"2021-09-14","type":"trial","source":"The Kathmandu Post","summary":"Two Covid-19 vaccines set to start trials in Nepal - The Kathmandu Post","headline":"Two Covid-19 vaccines set to start trials in Nepal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNMTgxRkNQZ3BUOU8yMmZiWlctdW00R1hOaGFHMFZfVkoyQ2VJb0lrbHI4N3BCWlViY1QzS3pTZTRiWnlxbTB1YU9neGRfS0ZVU1hRd1hvVFNHTERIem9TcDY4NTRldmYzY0lpLU5zMnlMMVVMbUQ4V3YwLWV2empIeF9iUUc5ZGQ5dm9EbTZ1VUxYVS1QQ29lU1ZzOUg5TFFuQnc0UVVWd1M4cUNM?oc=5","date":"2020-10-23","type":"pipeline","source":"Fierce Biotech","summary":"Sirnaomics nabs a major $105M funding round for next stage of its RNA work - Fierce Biotech","headline":"Sirnaomics nabs a major $105M funding round for next stage of its RNA work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBnM1M3bHE4cFlxNUh2Mkh4cEFLb295QjYxaGJmYWNod2lMQkFNNEpHMHpDeWdERzRDMmJCdDVtcmtIQlFZa1dPZTQ0QXBWSmxtTkFZSk9WdC1XX09VVW40?oc=5","date":"2019-12-30","type":"pipeline","source":"Straits Research","summary":"Vaccines Market Size, Top Share, Global Trends And Report By 2033 - Straits Research","headline":"Vaccines Market Size, Top Share, Global Trends And Report By 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFA2bkd6VE5oR3FCbTdfYUdGYlIzTWFwUGZCVjlHbjFQVjRZM3NJOVZoaVBwSTlIM3ZWOU9NZm0wOFZteHdueVZZTVNJeGdsdGhZMkxsTkl3VndONnk5M0gybWNYb1NjaVE4LWltM3FZVXplcUM4?oc=5","date":"2015-05-15","type":"pipeline","source":"Allied Market Research","summary":"Meningococcal Vaccines Market Size, Share & Growth, 2032 - Allied Market Research","headline":"Meningococcal Vaccines Market Size, Share & Growth, 2032","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}